Actively Recruiting

Phase 2
Age: 20Years - 65Years
All Genders
NCT07122895

Sex Differences in NMDA-enhancing Treatment of Schizophrenia

Led by China Medical University Hospital · Updated on 2025-09-17

90

Participants Needed

1

Research Sites

232 weeks

Total Duration

On this page

Sponsors

C

China Medical University Hospital

Lead Sponsor

N

National Science and Technology Council, Taiwan

Collaborating Sponsor

AI-Summary

What this Trial Is About

Schizophrenia differs between sexes in clinical symptoms and functional outcome. Negative symptoms are the core pathology of this disease. NMDA receptor (NMDAR) dysfunction is a key factor in negative symptoms. This study aims to examine the sex difference in the efficacy of an NMDA-enhancer (NMDAE) for the treatment of negative symptoms in schizophrenia.

CONDITIONS

Official Title

Sex Differences in NMDA-enhancing Treatment of Schizophrenia

Who Can Participate

Age: 20Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Have a DSM-5 diagnosis of schizophrenia
  • Stable mental condition for at least 6 months before baseline with predominantly negative symptoms for 6 months or more
  • Minimum baseline total score of 40 on the Scale for Assessment of Negative Symptoms
  • Minimum baseline score of 24 on the negative subscale of the Positive and Negative Syndrome Scale
  • Maximum score of 3 on each item of the Positive and Negative Syndrome Scale-positive subscale
  • Physically healthy with clinically insignificant blood and biochemical lab tests
  • Fixed dose of antipsychotics for at least 6 months with no changes allowed during the 12-week study
  • Sufficient education to communicate and complete study assessments
  • Agree to participate and provide written informed consent
Not Eligible

You will not qualify if you...

  • Diagnosis of intellectual disability or substance (including alcohol) use disorder
  • History of epilepsy, head trauma, or serious medical or central nervous system diseases other than schizophrenia
  • Clinically evident depressive symptoms or a baseline score greater than 7 on the Hamilton Depression Rating Scale-17 items
  • Clinically relevant parkinsonism or baseline score greater than 3 on the first eight items of the Simpson-Angus Scale
  • Pregnancy or lactation
  • Inability to follow the study protocol

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Psychiatry, China Medical University Hospital

Taichung, Taiwan

Actively Recruiting

Loading map...

Research Team

H

Hsien-Yuan Lane, M.D., Ph.D

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Sex Differences in NMDA-enhancing Treatment of Schizophrenia | DecenTrialz